03:18 PM EDT, 04/23/2024 (MT Newswires) -- Novartis ( NVS ) said Tuesday it received approval from the US Food and Drug Administration for Lutathera as therapy for children with gastroenteropancreatic neuroendocrine tumors.

The approval is based on the results of a trial that evaluated Lutathera in patients aged between 12 and 18 years, which indicated a safety profile consistent with Lutathera's trial in adults, the company said.

Lutathera the first therapy specifically approved for use in pediatric patients, it said.

Novartis ( NVS ) shares were more than 2% higher in recent trading.

Price: 97.23, Change: +2.10, Percent Change: +2.21